Chemotherapy Induced Nausea and Vomiting is an indication for drug development with over 20 pipeline drugs currently active. According to GlobalData, preregistered drugs for Chemotherapy Induced Nausea and Vomiting have a 92.86% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Chemotherapy Induced Nausea and Vomiting compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Chemotherapy Induced Nausea and Vomiting overview
Chemotherapy-induced nausea and vomiting (CINV) is nausea and vomiting that results specifically from treatment with chemotherapy drugs. Other symptoms include a rapid heart rate, sweating, dizziness, and increased saliva. Risk factors include age, drug, dose, and the schedule and route of the drug’s administration.
For a complete picture of PTSR and LoA scores for drugs in Chemotherapy Induced Nausea and Vomiting, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.